In this case-control study we recruited infants with bilateral cataract up to the age of 12 months, who attended three major tertiary care facilities in Tanzania from November 2016 to August 2017: KCMC Hospital (Kilimanjaro), Comprehensive Community Based Rehabilitation for Tanzania (CCBRT) Disability Hospital (Dar es Salaam) and Muhimbili National Hospital (MNH) (Dar es Salaam). All children underwent preliminary evaluation for study eligibility (as potential cases or controls) by pediatric ophthalmologists (GF, JM, PN, and SV) prior to enrolment. All children less than 12 months of age with bilateral significant cataract were eligible as cases.
Controls were children less than 12 months of age without cataract or obvious ocular pathology and/or any other systemic problems. They were selected from population of children less than 5 years of age attending reproductive and child health clinics for routine immunizations and nutrition check at the same hospitals. Case and control groups were all age-matched. Only cases were assessed for anemia using Haemo Control Hemoglobin Analyser. Haemoglobin level less than 7.0 g/dL were classified as severe anemia, 7.0 to 9.9 g/dL as moderate anemia and 10.0 - 10.9 g/dL as mild anemia (
8). Birth weights were recorded; low birth weight was defined as ≤ 2.5 kilograms (
9). Cases were also assessed for co-morbid eye diseases (microphthalmos: corneal diameter < 9.5 mm and/or axial length < 17 mm, nystagmus, and retinopathy) by ophthalmologists, and for systemic abnormalities (delayed milestones, congenital heart defects, prematurity and other malformations) by a paediatrician. Developmental milestones were evaluated using a milestones chart designed specifically for staff providing services for children (
10), and apparent delays were recorded.
During cataract surgery paediatric ophthalmologists collected lens tissue from one eye, and saliva samples and dried blood spots (DBS) from eligible cases. Paediatric ophthalmologists also collected saliva and DBS from eligible controls. DBS were collected from a heel prick using contact-activated lancets (BD Microtainer, Becton Dickinson) and were air-dried. Once dry, DBS were stored at -20°C until analysis. Following surgical extraction, lens tissue specimens from cataract cases were placed in 1 mL of RNAlater® (Invitrogen) and stored at 4°C overnight, then at -80°C until RNA/DNA extraction. Saliva samples from cases and controls were collected from the buccal mucosa using a sterile polyester-tipped cytobrush (SLS) and were stored in 400 µL RNAlater® at 4°C overnight then at -80°C until RNA/DNA extraction. The cytobrush was inserted into the child’s mouth between the cheek and teeth of the lower jaw and rotated five times so that it was fully coated in saliva.
DBS were eluted and tested for IgM antibodies to rubella virus and HCMV using Enzygnost immunoassays (Siemens Healthcare), performed following the manufacturer’s instructions.
Lens tissue samples were thawed, centrifuged for one minute and the supernatant discarded. Two hundred microliters of phosphate buffer saline (PBS) was added and the sample was transferred to a sterile Biomasher II® micropestle (Kimble Chase). The tissue was manually disrupted for one minute on ice, then centrifuged briefly to pellet cell debris. Two hundred microliters of supernatant was extracted using the QIAamp Cador (Qiagen) pathogen mini kit. Saliva samples were thawed and the cytobrush was transferred to a 2 mL tube containing 200 µL PBS. Tubes were vortexed for one minute and centrifuged briefly, following which the brush was discarded and the sample was vortexed for another minute. The sample was pulse centrifuged and 200 µL of supernatant was extracted using the QIAamp Cador pathogen mini kit following the manufacturer’s instructions.
Sample storage and extraction protocols were initially optimised using pilot clinical samples spiked with rubella virus (WHO reference reagent) and HCMV (WHO international standard) from the UK National Institute for Biological Standards and Control.
Reverse-transcription qPCR for detection of rubella virus RNA and qPCR for the detection of HCMV DNA were performed on a Rotor-Gene Q thermal cycler (Qiagen) using commercially available kits (LifeRiver, ZJ-Biotech) following the manufacturers’ instructions.
Pearson’s chi-square test analysis was used to compare the difference in distribution of rubella and HCMV infections between cases and controls. Birth weight was categorized into four levels (< 2.0 kg = severe low birth weight, 2.0 - 2.5 = moderate low birth weight, and > 2.5 kg = normal birth weight) and was compared using chi-square tests. All plausible factors associated with HCMV and rubella infection (exposure variables) were tested in univariate analyses and a multivariate model. All these variables were treated as categorical variables. Simple linear regression was performed to show the relationship between age and HCMV saliva concentrations in cases and controls.
The research ethics committees of London School of Hygiene and Tropical Medicine, UK [ref: 10487‑1], Tanzania, the national Institute of Medical Research [ref: NIMRlHQ/R.8a/Vol.IXI2245], and Kilimanjaro Christian Medical University College [REF: No.913], granted ethical clearance.